BioLife Sciences Inc. (BLFE) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBioLife Sciences Inc. (BLFE) trades at $0.0001. BioLife Sciences Corp. specializes in antibacterial solutions and non-contact human temperature screening technologies, offering products like sanitizing wipes, UV sterilization equipment, and touch-free vending systems. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for BLFE: BLFE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BioLife Sciences Inc. (BLFE) Healthcare & Pipeline Overview
BioLife Sciences Inc. develops and distributes antibacterial solutions and non-contact human temperature screening technologies, including sanitizing wipes, UV sterilization, and touch-free vending systems. The company, founded in 2018, addresses evolving hygiene and public health monitoring needs within the healthcare sector from its base in Canada.
What Is the Investment Thesis for BLFE?
BioLife Sciences Inc. operates in the growing hygiene and public health technology markets, driven by increased awareness and demand for germ control and non-contact health screening. The company's diverse product portfolio, encompassing antibacterial solutions, UV sterilization, and touch-free systems, positions it to capture opportunities across multiple segments. While the company is relatively young, founded in 2018, its focus on licensing and distribution allows for potentially scalable market penetration. Financially, BLFE currently faces significant challenges, indicated by a negative profit margin of -308.0% and a gross margin of -239.3%, reflecting early-stage operational inefficiencies or high cost of revenue relative to sales. The market capitalization is minimal at $0.00B, suggesting a micro-cap or nano-cap status. However, the ongoing demand for hygiene solutions and evolving public health protocols could serve as long-term catalysts for revenue growth, provided the company can improve its operational efficiency and achieve positive margins. The beta of -2290.12 suggests extreme volatility and inverse correlation, which warrants careful consideration for investors evaluating market risk.
Based on FMP financials and quantitative analysis
BLFE Key Highlights
Market Capitalization of $0.00B, indicating a micro-cap or nano-cap company status.
- Profit Margin stands at -308.0%, reflecting substantial net losses relative to revenue.
- Gross Margin is -239.3%, suggesting that the cost of goods sold significantly exceeds revenue.
- Beta of -2290.12 indicates extreme historical volatility and an inverse relationship with the broader market.
- Specializes in a diverse portfolio including antibacterial solutions, UV sterilization, and non-contact temperature screening technologies.
Who Are BLFE's Competitors?
BLFE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| GCTK GlucoTrack, Inc. | $1.21 | -14.18% | — | |
| LUCY Innovative Eyewear, Inc. | $0.89 | -3.14% | $5.62M | — |
| FEMY Femasys Inc. | $2.05 | -2.38% | $6.19M | — |
| RGNT Regentis Biomaterials Ltd. | $1.85 | +1.09% | $13.0M | 64 5-pillar |
| MLSS Milestone Scientific Inc. | $0.38 | -7.58% | $33.4M | — |
| HBIO Harvard Bioscience, Inc. | $8.34 | +2.58% | $37.6M | — |
| NEPH Nephros, Inc. | $3.67 | 0.00% | $39.8M | 33 5-pillar |
| POCI Precision Optics Corporation, Inc. | $4.46 | +4.45% | $48.8M | 37 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BLFE's Key Strengths?
Diverse product portfolio addressing multiple hygiene and health monitoring needs.
- Involvement in both product development (licensing) and distribution channels.
- Focus on high-demand areas like antibacterial solutions and non-contact screening.
- Agile operational structure with a small team, potentially allowing for quick adaptation.
What Are BLFE's Weaknesses?
Extremely negative profit margin (-308.0%) and gross margin (-239.3%) indicating severe financial challenges.
- Very small employee base (3 employees) may limit scalability and operational capacity.
- Minimal market capitalization ($0.00B) suggests limited access to capital and market influence.
- Unknown disclosure status on OTC market raises transparency concerns for investors.
What Are the Key Risks for BLFE?
Extremely negative profit and gross margins indicate severe operational and financial challenges, raising concerns about long-term viability.
- Intense competition from larger, better-capitalized companies in the hygiene and medical supplies sectors could limit market penetration.
- Limited public financial disclosure and 'OTC Other' tier status pose significant transparency and liquidity risks for investors.
- Reliance on a small employee base (3 employees) may constrain growth, innovation, and operational scalability.
- Rapid technological advancements or shifts in public health guidelines could render current products less competitive or obsolete.
What Threats Does BLFE Face?
- Intense competition from larger, more established players in hygiene and medical device markets.
- Rapid technological obsolescence requiring continuous R&D investment.
- Regulatory changes or new health guidelines impacting product demand or approval processes.
- Economic downturns reducing discretionary spending on hygiene solutions and new technologies.
What Are BLFE's Competitive Advantages?
- Diverse product portfolio spanning antibacterial solutions, UV sterilization, and non-contact screening technologies.
- Focus on both product development (licensing) and distribution, allowing for broad market reach.
- Proprietary anti-microbial fabric technology offers integrated, long-lasting protection.
- Early mover advantage in specific touch-free vending and marketplace systems addressing hygiene concerns.
- Professional electrostatic disinfection services provide a specialized, effective solution for comprehensive coverage.
What Does BLFE Do?
BioLife Sciences Corp. (BLFE), established in 2018 and headquartered in Mississauga, Canada, operates within the healthcare sector, specifically focusing on medical instruments and supplies. The company's core business revolves around the creation, licensing, and distribution of two primary categories of solutions: advanced antibacterial products and innovative non-contact human temperature screening technologies. This dual focus positions BioLife Sciences to address critical public health and hygiene demands, which have seen increased emphasis in recent years. Its product portfolio is diverse, reflecting a multi-faceted approach to germ control and health monitoring. Key offerings include a range of sanitizing wipes designed for various applications, providing convenient and effective disinfection. Beyond consumables, BioLife Sciences also provides sophisticated ultraviolet (UV) sterilization equipment, which is utilized for deeper, more thorough disinfection of surfaces and environments. The company extends its service offerings to include professional electrostatic disinfection, a method known for its efficiency in covering large areas and complex surfaces with antimicrobial agents. Further diversifying its product line, BioLife Sciences develops specialized anti-microbial fabrics, which integrate germ-fighting properties directly into materials for sustained protection. A forward-looking aspect of its business is the development of innovative touch-free vending or marketplace systems, aligning with the growing demand for automated, hygienic retail and distribution solutions. Operating with a lean team of three employees, BioLife Sciences maintains a focused approach to product development and market penetration within its niche segments of the healthcare industry.
What Products and Services Does BLFE Offer?
- Develops and licenses antibacterial solutions for various applications.
- Distributes advanced non-contact human temperature screening technologies.
- Offers sanitizing wipes for personal and professional hygiene.
- Provides ultraviolet (UV) sterilization equipment for surface and air disinfection.
- Delivers professional electrostatic disinfection services for comprehensive germ control.
- Creates specialized anti-microbial fabrics for integrated pathogen protection.
- Innovates touch-free vending and marketplace systems for hygienic product distribution.
How Does BLFE Make Money?
- Generates revenue through the sale and distribution of proprietary antibacterial products like wipes and fabrics.
- Licenses its antibacterial solutions and non-contact temperature screening technologies to other entities.
- Provides professional services, specifically electrostatic disinfection, on a contractual basis.
- Sells and distributes advanced equipment, including UV sterilization units and non-contact screening devices.
- Develops and deploys touch-free vending systems, potentially through sales or revenue-sharing models.
What Industry Does BLFE Operate In?
BioLife Sciences Inc. is positioned within the Medical - Instruments & Supplies industry, a segment of the broader Healthcare sector that is continually evolving with technological advancements and shifting public health priorities. The company's focus on antibacterial solutions and non-contact temperature screening places it at the intersection of two significant market trends: enhanced hygiene protocols and preventive health monitoring. The global market for disinfectants and sanitizers has experienced sustained growth, particularly post-2020, driven by increased health consciousness and institutional requirements. Similarly, the demand for non-contact screening technologies, including thermal scanners, has expanded beyond traditional medical settings into public spaces and commercial environments. BioLife Sciences competes with a range of established players and emerging innovators in these fragmented markets, from large chemical companies offering sanitization products to specialized medical device manufacturers. Its strategy of licensing and distributing a diverse product set, from wipes to UV equipment and electrostatic services, aims to carve out a niche by offering comprehensive hygiene and screening solutions.
Who Are BLFE's Key Customers?
- Healthcare facilities and medical institutions requiring advanced disinfection and screening.
- Commercial businesses and public spaces seeking enhanced hygiene protocols.
- Consumers through retail channels for personal sanitization and protective products.
- Facility management companies utilizing professional disinfection services.
- Organizations and venues implementing touch-free health monitoring and vending solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
BioLife Sciences Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Key Financial Metrics
Return on equity for BioLife Sciences Inc. stands at 367.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
BioLife Sciences Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Henderson, US. The company is led by CEO Justin De Four. BLFE has traded publicly since 2005.
BLFE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
BLFE Latest News
No recent news available for BLFE.
BLFE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BLFE.
Price Targets
Wall Street price target analysis for BLFE.
BLFE MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BLFE; grades run from A+ (80-100) to F (below 30).
Leadership: Justin De Four
Chief Executive Officer
Justin De Four serves as the Chief Executive Officer of BioLife Sciences Inc., a role he has held since the company's inception in 2018. His leadership has been instrumental in shaping the company's strategic direction and product portfolio from its founding. With a background focused on developing and bringing innovative solutions to market, Mr. De Four has guided BioLife Sciences through its initial stages of establishing its core business in antibacterial solutions and non-contact temperature screening technologies. His responsibilities encompass overseeing the creation, licensing, and distribution efforts, managing the company's lean operational structure and its small team of three employees.
Track Record: Under Justin De Four's leadership, BioLife Sciences Inc. has successfully established a diverse product portfolio since its founding in 2018. He has overseen the introduction of various antibacterial solutions, including sanitizing wipes and specialized anti-microbial fabrics, alongside the development and distribution of UV sterilization equipment and non-contact temperature screening technologies. His strategic decisions have focused on positioning the company to address evolving public health and hygiene demands, culminating in the establishment of its current operational framework and market offerings.
BLFE OTC Market Information
BioLife Sciences Inc. trades on the OTC market under the 'OTC Other' tier. This tier represents companies that do not meet the disclosure requirements for OTCQX or OTCQB, or are not eligible for the Pink Current Information tier. Companies in 'OTC Other' may not provide any public financial information or may have limited reporting. This contrasts sharply with major exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial reporting, corporate governance, and minimum share prices. Even within the OTC market, 'OTC Other' has fewer disclosure obligations than OTCQX (highest tier, strong financial standards) or OTCQB (venture market, requires audited financials).
- OTC Tier: OTC Other
- Limited or no public financial disclosure, making fundamental analysis extremely challenging.
- Low liquidity and wide bid-ask spreads, leading to difficulty in trading shares.
- Increased susceptibility to fraud and manipulation due to less regulatory oversight.
- Potential for significant price volatility due to low trading volume and limited investor interest.
- Difficulty in obtaining financing or attracting institutional investment due to lack of transparency and market perception.
- Verify any available financial statements directly from company filings, if any exist.
- Research the company's management team beyond what is publicly stated, if possible.
- Investigate any news or press releases from independent, reputable sources.
- Understand the company's business model and revenue generation strategy in detail.
- Assess the competitive landscape and the company's actual market position.
- Evaluate the company's operational history and any past legal or regulatory issues.
- Consider the potential for dilution if the company seeks to raise capital through share issuance.
- Clear articulation of its product portfolio and business activities (antibacterial solutions, temperature screening).
- Identified physical headquarters in Mississauga, Canada.
- Specific founding year (2018) provides a timeline for its establishment.
- Named CEO (Justin De Four) provides a point of contact for leadership.
- Involvement in relevant and growing markets (hygiene, non-contact health tech).
BioLife Sciences Inc. Healthcare Stock: Key Questions Answered
How does BioLife Sciences Inc. position itself in the antibacterial solutions market?
BioLife Sciences Inc. positions itself in the antibacterial solutions market by offering a multi-faceted approach that spans various product types and services.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Market capitalization of $0.00B implies a very small or unlisted market value, which is unusual and may indicate data limitations or extreme illiquidity.
- Details on CEO's full career history and specific achievements are limited to company founding and product portfolio establishment due to source data constraints.
- Disclosure status for OTC is explicitly stated as 'Unknown' in the source, which is reflected in the analysis.